The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of
antiretroviral (ARV) medications before exposure to HIV. This study will examine the
feasibility of different methods of dosing for a PrEP regimen. Three methods of delivery will
be compared: daily, time-based, and event-based.
Phase:
Phase 2
Details
Lead Sponsor:
HIV Prevention Trials Network National Institute of Allergy and Infectious Diseases (NIAID)